Piramal Enterprises leads gains on S&P BSE 200 this quarter
The investment focus shall include the Mumbai, Delhi (NCR), Bangalore, Pune and Chennai
Joint venture to set up fund with corpus of $250 million
Firm's 2nd buyout in pain management space in 3 months
Also annouces demerger of healthcare, financial services
Upfront payment of $155 mn to be made to Janssen Pharmaceutica for acquisition
Icra has assigned a rating of AA with a stable outlook to non-convertible debentures worth Rs 7,500 crore and a rating of A1+ (investment grade) to Rs 3,000 crore worth of commercial paper/short-term debt that PFPL proposes to raise
They are going to invest more than $1 bn in the space over the next few years
Piramal Enterprises and Canada Pension Plan Investment Board formed a $500 mn joint venture; both were to bring in $250 mn each
This potential transaction is expected to be completed by end of August
Deal value is $53 million; Piramal hopes to tap high potency Active Pharmaceutical Ingredients market
The company, however, did not specify on what it intends to do with the money
The company, however, did not specify on what it intends to do with the money
The Mumbai-based entity, however, has not specified the purpose of raising the fund
Thus far in 2016, the stock outperformed the market by gaining 32% as compared to 1.4% decline in Sensex.
The company's total revenue rose 34% at Rs 1,734 crore during Q4 FY2016, against Rs1,298 crore during Q4 FY2015
Full-year profit at Rs 951 cr vs Rs 2,850 cr in FY15; firm says figures not comparable due to acquisitions and divestitures